Loading…
This entity appears on both sides of lobbying disclosures. The firm tab shows registrant-reported income; the client tab shows client-reported lobbying spend. Contract awards are separate and are not included here.
Lobbying Spend
$3.3M
Filings
67
Firms Hired
4
Active Period
2018–2022
Client-reported lobbying expenses on LDA filings
Lobbying firms retained by this client; amounts are client-reported expenses when available
Government entities explicitly identified as targets in LDA filings
Most frequently reported lobbying issues
Bill numbers found in source-reported LDA specific issue text; broad topic matches are excluded
Sickle Cell Disease Treatment Centers Act of 2022
2022 · fourth_quarter · Firm: NVG, LLC
H.R.8855/S.4866 - Sickle Cell Disease Treatment Centers Act of 2022.
Client expense: — · Firm income: $50,000
Matched citations: H.R.8855
Sickle Cell Disease Treatment Centers Act of 2022
2022 · fourth_quarter · Firm: NVG, LLC
H.R.8855/S.4866 - Sickle Cell Disease Treatment Centers Act of 2022.
Client expense: — · Firm income: $50,000
Matched citations: S.4866
Sickle Cell Disease Treatment Centers Act of 2022
2022 · fourth_quarter · Firm: NVG, LLC
H.R.8855/S.4866 - Sickle Cell Disease Treatment Centers Act of 2022.
Client expense: — · Firm income: $50,000
Matched citations: H.R.8855
Sickle Cell Disease Treatment Centers Act of 2022
2022 · fourth_quarter · Firm: NVG, LLC
H.R.8855/S.4866 - Sickle Cell Disease Treatment Centers Act of 2022.
Client expense: — · Firm income: $50,000
Matched citations: S.4866
Sickle Cell Disease Comprehensive Care Act
2022 · fourth_quarter · Firm: W STRATEGIES, LLC
Education about access to innovative sickle cell disease therapies and proposed legislation to increase funding and care coordination for patients with sickle cell disease. H.R.6216/S.4866 - Sickle Cell Disease Comprehensive Care Act.
Client expense: — · Firm income: $50,000
Matched citations: H.R.6216
Sickle Cell Disease Treatment Centers Act of 2022
2022 · fourth_quarter · Firm: W STRATEGIES, LLC
Education about access to innovative sickle cell disease therapies and proposed legislation to increase funding and care coordination for patients with sickle cell disease. H.R.6216/S.4866 - Sickle Cell Disease Comprehensive Care Act.
Client expense: — · Firm income: $50,000
Matched citations: S.4866
Sickle Cell Disease Treatment Centers Act of 2022
2022 · third_quarter · Firm: NVG, LLC
Legislation to create care sickle cell treatment centers. H.R.8855/S.4866 - Sickle Cell Disease Treatment Centers Act of 2022.
Client expense: — · Firm income: $50,000
Matched citations: H.R.8855
Sickle Cell Disease Treatment Centers Act of 2022
2022 · third_quarter · Firm: NVG, LLC
Legislation to create care sickle cell treatment centers. H.R.8855/S.4866 - Sickle Cell Disease Treatment Centers Act of 2022.
Client expense: — · Firm income: $50,000
Matched citations: S.4866
Elijah E. Cummings Lower Drug Costs Now Act
2021 · fourth_quarter · Firm: GLOBAL BLOOD THERAPEUTICS
Sickle cell disease education; HR 3 - Elijah E. Cummings Lower Drug Costs Now Act
Client expense: $130,000 · Firm income: —
Matched citations: HR 3
Elijah E. Cummings Lower Drug Costs Now Act
2021 · third_quarter · Firm: GLOBAL BLOOD THERAPEUTICS
Sickle cell disease education; HR 3 - Elijah E. Cummings Lower Drug Costs Now Act
Client expense: $210,000 · Firm income: —
Matched citations: HR 3
Elijah E. Cummings Lower Drug Costs Now Act
2020 · fourth_quarter · Firm: GLOBAL BLOOD THERAPEUTICS
SCD funding; Drug pricing (HR 3); access to SCD treatment and care
Client expense: $170,000 · Firm income: —
Matched citations: HR 3
Elijah E. Cummings Lower Drug Costs Now Act
2020 · third_quarter · Firm: GLOBAL BLOOD THERAPEUTICS
Drug pricing (HR 3) Drug Pricing Transparency Proposals International Pricing Index proposals
Client expense: $130,000 · Firm income: —
Matched citations: HR 3
Elijah E. Cummings Lower Drug Costs Now Act
2020 · second_quarter · Firm: GLOBAL BLOOD THERAPEUTICS
Drug pricing (HR 3) Drug Pricing Transparency Proposals International Pricing Index proposals
Client expense: $131,000 · Firm income: —
Matched citations: HR 3
Elijah E. Cummings Lower Drug Costs Now Act
2020 · first_quarter · Firm: GLOBAL BLOOD THERAPEUTICS
Drug pricing (HR 3) Drug Pricing Transparency Proposals International Pricing Index proposals
Client expense: $154,180 · Firm income: —
Matched citations: HR 3
Lower Costs, More Cures Act of 2019
2020 · first_quarter · Firm: W STRATEGIES, LLC
S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019.
Client expense: — · Firm income: $30,000
Matched citations: H.R.19
Elijah E. Cummings Lower Drug Costs Now Act
2020 · first_quarter · Firm: W STRATEGIES, LLC
S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019.
Client expense: — · Firm income: $30,000
Matched citations: H.R.3
Prescription Drug Pricing Reduction Act of 2019
2020 · first_quarter · Firm: W STRATEGIES, LLC
S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019.
Client expense: — · Firm income: $30,000
Matched citations: S.2543
Lower Costs, More Cures Act of 2019
2019 · fourth_quarter · Firm: W STRATEGIES, LLC
Access to innovative therapies in the Medicaid program. S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019.
Client expense: — · Firm income: $30,000
Matched citations: H.R.19
Education about access to innovative therapies, especially in sickle cell disease. H.R.2113: Prescription Drug STAR Act.
Client expense: — · Firm income: $30,000
Matched citations: H.R.2113
Elijah E. Cummings Lower Drug Costs Now Act
2019 · fourth_quarter · Firm: W STRATEGIES, LLC
Access to innovative therapies in the Medicaid program. S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019.
Client expense: — · Firm income: $30,000
Matched citations: H.R.3
Prescription Drug Pricing Reduction Act of 2019
2019 · fourth_quarter · Firm: W STRATEGIES, LLC
Access to innovative therapies in the Medicaid program. S.2543: Prescription Drug Pricing Reduction Act of 2019. H.R.3: Lower Drug Costs Now Act of 2019. H.R.19: Lower Costs, More Cures Act of 2019.
Client expense: — · Firm income: $30,000
Matched citations: S.2543
Elijah E. Cummings Lower Drug Costs Now Act
2019 · fourth_quarter · Firm: GLOBAL BLOOD THERAPEUTICS
Drug pricing (HR 3) Drug Pricing Transparency Proposals International Pricing Index proposals
Client expense: $154,100 · Firm income: —
Matched citations: HR 3
Education about access to innovative therapies, especially in sickle cell disease. H.R.2113: Prescription Drug STAR Act.
Client expense: — · Firm income: $30,000
Matched citations: H.R.2113
Prescription Drug Pricing Reduction Act of 2019
2019 · third_quarter · Firm: W STRATEGIES, LLC
Access to innovative therapies in the Medicaid program. S.2543: Prescription Drug Pricing Reduction Act of 2019.
Client expense: — · Firm income: $30,000
Matched citations: S.2543
Elijah E. Cummings Lower Drug Costs Now Act
2019 · third_quarter · Firm: GLOBAL BLOOD THERAPEUTICS
Drug pricing (HR 3) Drug Pricing Transparency Proposals International Pricing Index proposals
Client expense: $137,500 · Firm income: —
Matched citations: HR 3
Source: Senate LDA